Figure 5.

Changes in dose response on targeting IL-6/sIL-6Rα complex along with IL-6 or IL-6Rα are shown. The data points show simulated decrease in serum CRP as percent of the baseline value after a 12-week treatment with intravenous drug administration at 4-week intervals. (a) Compared with the case when only IL-6 was targeted (solid lines), the efficacy of the drug was predicted to be higher when both IL-6 and IL-6/sIL-6Rα were targeted (dashed lines). (b) Targeting the complex (dashed lines) did not cause any significant improvement in CRP suppression compared with the case when only IL-6Rα was targeted (solid lines). CRP, C-reactive protein; IL, interleukin.